• 沒有找到結果。

走路方案對急性骨髓性白血病病患接受化學治療期間疲憊改善之效 果

N/A
N/A
Protected

Academic year: 2021

Share "走路方案對急性骨髓性白血病病患接受化學治療期間疲憊改善之效 果"

Copied!
2
0
0

加載中.... (立即查看全文)

全文

(1)

走路方案對急性骨髓性白血病病患接受化學治療期間疲憊改善之效

Effects of walking program on decreasing fatigue in acute myelogenous leukemia patients receiving chemotherapy

中文摘要

本研究目的在於確立走路方案改善急性骨髓性白血病病患接受化學治療期間疲 憊之效果。研究設計採縱貫式重複測量之類實驗法,以方便取樣方式於中部某醫 學中心,針對診斷為急性骨髓性白血病,且住院期間接受化學治療之病患,收案 個數共 15 人,實驗組 7 人,控制組 8 人。收案時間為化學治療當日(化療前)、

化學治療後第七天、第十四天及第二十一天,共四次。走路方案為每天走一次 10 分鐘,每週平均執行 5 天(含測試),共三週,訓練期間之運動強度設在休息時 每分鐘心跳加上 30(HRresting+30)的範圍內。研究工具為 12 分鐘走路測試、簡明 疲憊量表、症狀困擾量表、情緒狀態量表-焦慮及憂鬱次量表及生命徵象(含血 壓、體溫、心跳及呼吸)之測量。所得資料以描述性統計、卡方檢定、t 檢定、

Shapiro-Wilk 常態分佈檢定、雙/單因子重複測量變異數分析。研究結果顯示:(1) 實驗組病患的 12 分鐘走路距離增加 35%,控制組病患的距離減少 26%;(2)實驗 組病患的疲憊程度、疲憊干擾日常生活程度、症狀困擾及情緒障礙之改善效果皆 較控制組佳。

本研究結果由於樣本數少,以致實驗組與控制組之差異未能呈現統計上之顯著意 義。但與多數運動研究結果一致,亦即活動/運動在癌症治療期間的好處是不可 磨滅的。因此,在臨床照護中,於此類住院病患接受化學治療期間,執行適當的 走路活動可有助於降低疲憊。

英文摘要

The purpose of this pilot study is to examine the effects of walking program on reducing fatigue in acute myelogenous leukemia (AML) patients receiving

chemotherapy. We used a longitudinal repeated-measure quasi-experimental research design for this study. The eligible subjects were AML patients who received

chemotherapy. Patients were recruited using convenient sampling from a medical center in Middle Taiwan. Patients in the training group (n=7) had a 10-minute walk daily for 5 days a week (including test day) after chemotherapy. The training program continued for 3 weeks. The heart rate during training was controlled below the resting heart rate per minute plus 30 (HRresting + 30). 8 patients were in the control group.

All patients were interviewed four times: on the first day of chemotherapy (before treatment), and on the 7th, 14th, and 21st day after chemotherapy. We used the

(2)

following instruments to measure the variables: 12-min walking test, Brief Fatigue Inventory (BFI), Symptom Distress Scale- Chinese Modified Form (SDS-CMF), Profile of Mood States (POMS)- Anxiety and Depression subscales, and vital signs measurement.

Data were analyzed using descriptive analyses, Chi-square test, t test, Shapiro-Wilk normality test, and two / one factor repeated measure ANOVA. The distance of 12-min walk increased 35% in the training group, and decreased 26% in the control group. The improving effects of the training group is better than that of the control group on the degree of fatigue, the degree of ADL interference of fatigue, symptom distress, and mood disturbance.

Even though our data did not show a significant difference between the training and control groups due to the small sample size, we did find an agreement with most current exercise interventions studies supporting the benefits of activity/exercise during cancer treatment. In conclusions, proper walking activity may help to reduce fatigue while the cancer inpatients during chemotherapy.

參考文獻

相關文件

BIBW 2992 + vinorelbine 或 trastuzumab+vinorelbine 治療 先前曾用 trastuzumab 治療無效,且過量表現 HER2 之轉

SF15140A 楊勝舜 利用 JKB-122 評估對於經干擾素(長效 型或短效型)或干擾素和 Ribavirin 組合 治療沒有反應的 C 型肝炎病毒陽性患 者之肝臟功能 (丙胺酸轉胺酶

本案件為乳癌標準化化學藥物治療與個人化化學治 療處方手術前化學治療療效比較之國內多中心研 究,於 2008 年 8 月 1 日由

IRB 編號 CE20018A 計畫主持人 王振宇 計畫名稱 電子病歷警示系統對改善敗血症病患預後之影響 審查意見

患者,使用口服 BIBF 1120 加標準 pemetrexed 療法,相較於 安慰劑加標準 pemetrexed 療法之功效與安全性的多中心、隨

liraglutide 對於第二型糖尿病病患的療效與安全性之臨床 試驗。 一個 26 週並再延長 26 週、隨機分配、三個治療

SF11310 張基晟 比較 Ipilimumab 加上 Etoposide/Platinum 與 Etoposide/Platinum

4 SF12207 黃文豊 一項隨機、雙盲、多中心試驗,比較 Denosumab 與 Zoledronic Acid (Zometa®)治療新診斷出多發性骨髓瘤